Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2013 Nov 12;12(12):2917–2928. doi: 10.1158/1535-7163.MCT-13-0572

Figure 2. PARP inhibition decreased tumor mass when administered under low levels of circulating estrogen.

Figure 2

(A) Strategy for therapy of PTEN-null tumors in a low estrogen milieu. (B) Treatment design. (C) PARP inhibition with low circulating estrogen levels significantly decreased tumor mass compared to vehicle treated controls (n=8 per group, p < 0.0001). (D) Both Olaparib and vehicle treated tumors contained neoplastic epithelial glands with lumens (a&d) that were pankeratin positive (b&e) but PTEN negative (c&f). Scale bars equal 5 mm in A&C and 100 μm in D.